Iterum Therapeutics (NASDAQ:ITRM) Downgraded to Hold Rating by Maxim Group

Iterum Therapeutics (NASDAQ:ITRM) was downgraded by equities researchers at Maxim Group from a “strong-buy” rating to a “hold” rating in a report released on Wednesday,Zacks.com reports.

Several other brokerages have also commented on ITRM. Weiss Ratings reiterated a “sell (e+)” rating on shares of Iterum Therapeutics in a research note on Monday, December 22nd. Wall Street Zen cut shares of Iterum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Iterum Therapeutics has a consensus rating of “Hold” and a consensus price target of $9.00.

Iterum Therapeutics Stock Performance

ITRM opened at $0.17 on Wednesday. Iterum Therapeutics has a one year low of $0.14 and a one year high of $1.50. The company has a market cap of $8.98 million, a P/E ratio of -0.22 and a beta of 2.96. The business’s 50-day simple moving average is $0.30 and its 200-day simple moving average is $0.50.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ITRM. OneDigital Investment Advisors LLC boosted its stake in shares of Iterum Therapeutics by 18.6% during the third quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock worth $128,000 after buying an additional 30,000 shares during the period. Virtu Financial LLC purchased a new stake in Iterum Therapeutics during the 3rd quarter valued at approximately $32,000. Jane Street Group LLC acquired a new stake in Iterum Therapeutics during the 2nd quarter worth approximately $92,000. Alchemi Wealth LLC acquired a new stake in Iterum Therapeutics during the 4th quarter worth approximately $90,000. Finally, Apollon Financial LLC grew its stake in shares of Iterum Therapeutics by 151.8% in the 4th quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock valued at $211,000 after purchasing an additional 380,000 shares during the last quarter. 9.21% of the stock is currently owned by institutional investors and hedge funds.

About Iterum Therapeutics

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).